Antiviral composition, antiviral protective film and method for producing same

The antiviral composition and film, utilizing metal-containing particles in a protective film structure, address the challenge of pathogen attachment and growth, offering effective antifungal, antibacterial, and antiviral protection with enhanced durability and safety.

JP7594570B2Active Publication Date: 2024-12-04NANYA PLASTICS CORP
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
JP2022165940
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2021-11-26
Filing Date
2022-10-17
Publication Date
2024-12-04
Estimated Expiration
2042-10-17

AI Technical Summary

Technical Problem

Existing technologies are inadequate in quickly and effectively reducing the attachment and proliferation of pathogens such as fungi, bacteria, and viruses on surfaces.

Method used

An antiviral composition comprising a resin material and metal-containing particles with sizes between 2 nm to 200 nm, applied in an antiviral protective film with a base, antiviral, and adhesive layers, where the metal-containing particles are greater than 0.1% by weight, providing broad-spectrum antifungal, antibacterial, and antiviral effects.

Benefits of technology

The antiviral protective film effectively reduces pathogen attachment and growth on surfaces, demonstrating excellent antifungal, antibacterial, and antiviral properties, with improved durability and safety for human contact.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007594570000002
    Figure 0007594570000002
  • Figure 0007594570000003
    Figure 0007594570000003
  • Figure 0007594570000001
    Figure 0007594570000001
Patent Text Reader

Abstract

To provide an antiviral composition and an antiviral protective film that are adapted to reduce adherence and / or growth of pathogen, and to provide a method for producing the same.SOLUTION: Provided is an antiviral composition that contains a resin material and a metal-containing particle having a particle size ranging from 2 nm to 200 nm, and in which the contained amount of the metal-containing particle is greater than 0.1 wt.% relative to the total weight of the antiviral composition.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a composition, a protective film, and a method for producing the same, and in particular to an antiviral composition, an antiviral protective film, and a method for producing the same. [Background technology]

[0002] In recent years, due to the rampant spread of influenza viruses and COVID-19, it has become apparent that it is important to quickly and effectively reduce the attachment and / or proliferation of pathogens (fungi, bacteria, viruses, etc.). Summary of the Invention [Problem to be solved by the invention]

[0003] The present invention contemplates antiviral compositions, antiviral protective films, and methods of making the same, adapted to reduce the attachment and / or growth of pathogens. [Means for solving the problem]

[0004] The present invention provides an antiviral composition comprising a resin material and metal-containing particles. The particle size of the metal-containing particles is in the range of 2 nm to 200 nm. The content of the metal-containing particles is more than 0.1 wt % relative to the total weight of the antiviral composition.

[0005] The present invention provides an antiviral protective film including a base layer, an antiviral layer, and an adhesive layer. The antiviral layer is disposed on a surface of the base layer. The antiviral layer is formed by an antiviral composition. The adhesive layer is disposed on the other surface of the base layer. The base layer is disposed between the antiviral layer and the adhesive layer.

[0006] The present invention provides a method for making an antiviral protective film, the method comprising the steps of: disposing a base layer; coating the base layer with an antiviral composition to form an antiviral layer; Effect of the Invention

[0007] Based on the above discussion, the antiviral compositions and antiviral protective films can reduce the attachment and / or growth of pathogens (e.g., fungi, bacteria, or viruses). [Brief description of the drawings]

[0008] The accompanying drawings are included to provide a further understanding of the invention, and are incorporated in and constitute a part of this specification. The drawings illustrate embodiments of the invention and, together with the illustrations, serve to explain the principles of the invention. [Figure 1] FIG. 1 is a schematic diagram of an antiviral protective film according to one embodiment of the present invention. [Diagram 2] FIG. 1 is a schematic diagram of the use of an antiviral protective film according to one embodiment of the present invention. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0009] In the following detailed description, for purposes of explanation and not limitation, exemplary embodiments disclosing specific details are set forth to provide a thorough understanding of various principles of the present invention. However, it will be apparent to those skilled in the art that, having benefit of this disclosure, the present invention can be practiced in other embodiments that depart from the specific details disclosed herein. Moreover, descriptions of well-known objects, methods and materials may be omitted so as not to obscure the description of various principles of the present invention.

[0010] Ranges can be expressed herein as from "about" a particular value to "about" another particular value, or directly as a particular value and / or another particular value. When expressing a range, another embodiment includes from one particular value and / or to another particular value. Similarly, when values ​​are expressed as approximations using the preposition "about", it is understood that the particular value forms another embodiment. It will be further understood that the endpoints of each range are clearly related to or independent of the other endpoint. In this specification, the description method of describing a particular value with "about" or directly expressing a particular value without "about" includes the particular value and the average of the particular value determined within the acceptable deviation by a person skilled in the art, taking into account the measurement value discussed and the measurement-related error of a certain number (e.g., errors caused by other factors such as the limitations of the measurement system, the propagation of errors in the calculation process, etc.). For example, the description method of a particular value with "about" or directly expressing a particular value without "about" can be expressed within a range of ±10% of the particular value.

[0011] As used herein, non-limiting terms (such as possible, may, for example, or other similar terms) refer to non-mandatory or optional implementation, inclusion, addition, or presence.

[0012] Unless otherwise defined, all terms used herein (including technical and scientific terms) have the same meaning as commonly understood by a person of ordinary skill in the art to which the present invention belongs. It is also understood that terms (such as those defined in commonly used dictionaries) should be interpreted as having a meaning consistent with the meaning of the relevant technical background, and should not be interpreted in an idealized or overly formal sense unless expressly defined herein.

[0013] Fig. 1 is a schematic diagram of an antiviral protective film according to one embodiment of the present invention. Fig. 2 is a schematic diagram of the use of an antiviral protective film according to one embodiment of the present invention.

[0014] Referring to Fig. 1, the antiviral protective film 100 may include an antiviral layer 110, a base layer 120, and an adhesive layer 130. The antiviral layer 110 may be formed from an antiviral composition. The detailed content of the antiviral composition is described in the following paragraphs. The base layer 120 is disposed on the antiviral layer 110. The adhesive layer 130 is disposed on the base layer 120.

[0015] In one embodiment, the base layer 120 may include a light-transmitting material. For example, the base layer 120 may include a polyester film or other suitable polymer film, but the invention is not limited thereto.

[0016] It should be noted that the terms "polyester," "polyester material," and the like, as used herein, refer to any type of polyester, particularly aromatic polyesters, and in particular to purified terephthalic acid (PTA) and ethylene glycol (EG) (i.e., polyethylene terephthalate (PET)). Further, polyesters herein may be, for example, polytrimethylene terephthalate, polybutylene terephthalate (PBT), polyethylene naphthalate, or combinations thereof.

[0017] In this embodiment, the polyester is preferably polyethylene terephthalate, polytrimethylene terephthalate, polybutylene terephthalate, or a combination thereof. It may also be a copolymer, specifically a copolymer obtained by using two or more dicarboxylic acids and / or two or more diol components.

[0018] 1 and 2, in an exemplary application of the antiviral protective film 100, the adhesive layer 130 of the antiviral protective film 100 may be adhered to an object 240 such that the antiviral layer 110 of the antiviral protective film 100 faces outward to reduce the attachment and / or growth of pathogens (e.g., fungi, bacteria, and / or viruses, etc.).

[0019] 1, the anti-viral protective film 100 may further include a release layer 140. The release layer 140 may be disposed on the adhesive layer.

[0020] For example, the antiviral protective film for sale may further include a release layer. Furthermore, in an exemplary application, the release layer may be peeled off so that the adhesive layer can be attached to the object. The location to which the object is attached may include the surface of an electronic product suitable for contact (e.g., a mobile phone or a touch screen, but the present invention is not limited thereto), or the surface of an object that may come into contact with a public environment (e.g., a desktop, a chair surface, a countertop, or a medical device, but the present invention is not limited thereto). In this way, the outwardly facing antiviral layer may reduce the attachment and / or proliferation of pathogens on the layer. Furthermore, the application method and / or use method of the antiviral protective film 100 are relatively simple.

[0021] In one embodiment, the antiviral layer has a pencil hardness of 2H or greater. Pencil hardness can be measured according to ASTM D3363-05 Standard Test Method for Film Hardness by Pencil Test.

[0022] In this embodiment, the antiviral composition used to form the antiviral layer may include a resin material and metal-containing particles. The particle size of the metal particles is in the range of 2 nm to 200 nm. The particle size of the metal particles within this range may have better dispersibility, overall antifungal, antibacterial, antiviral effects and / or durability. In addition, if the particle size of the metal particles is too large (e.g., greater than 200 nm), the haze of the entire antiviral protective film may be high, affecting the appearance (e.g., visually resembling a white hazy film surface).

[0023] In an embodiment, the content of metal-containing particles is greater than 0.1 weight percent (wt%) and less than 8.0wt% based on the total weight of the antiviral composition.If the content of metal particles is too low (e.g., less than 0.1wt%), its antifungal, antibacterial and / or antiviral ability may be reduced.If the content of metal-containing particles is too high (e.g., more than 8.0wt%), the appearance of the product may be deteriorated.

[0024] In one embodiment, the metal-containing particles are metal particles, metal salt particles, metal oxide particles, or selected from one of the group consisting of the above particles.

[0025] In one embodiment, the metal in the metal-containing particle is selected from one of the group consisting of silver, titanium, aluminum, nickel, cobalt, copper, zinc, iron, and manganese.

[0026] For example, the metal-containing particles may be selected from the group consisting of silver metal particles, titanium metal particles, aluminum metal particles, nickel metal particles, cobalt metal particles, copper metal particles, zinc metal particles, iron metal particles, manganese metal particles, silver salt particles, titanium salt particles, aluminum salt particles, nickel salt particles, cobalt salt particles, copper salt particles, zinc salt particles, iron salt particles, manganese salt particles, silver oxide particles, titanium oxide particles, aluminum oxide particles, nickel oxide particles, cobalt oxide particles, copper oxide particles, zinc oxide particles, iron oxide particles, and manganese oxide particles.

[0027] In one embodiment, the metal in the metal-containing particle is selected from two or more of the group consisting of silver, titanium, aluminum, nickel, cobalt, copper, zinc, iron, and manganese. In other words, the metal-containing particle has at least two or more elements selected from the group consisting of silver, titanium, aluminum, nickel, cobalt, copper, zinc, iron, and manganese. In one embodiment, the corresponding ionic states of at least two of the two or more metal elements may have different valences.

[0028] In one embodiment, the metal in the metal-containing particle is selected from two or more of the group consisting of silver, titanium, aluminum, nickel, cobalt, copper, zinc, iron, and manganese, and the metal-containing particle is selected from the group consisting of silver metal particles, silver salt particles, and silver oxide particles, i.e., the metal-containing particle is selected from at least one of the group consisting of silver metal particles, silver salt particles, and silver oxide particles, and the metal in the metal-containing particle is selected from one or more of the group consisting of titanium, aluminum, nickel, cobalt, copper, zinc, iron, and manganese.

[0029] In one embodiment, the metal in the metal-containing particles is selected from two or more of the group consisting of silver, titanium, aluminum, nickel, cobalt, copper, zinc, iron, and manganese, and the metal-containing particles are selected from the group consisting of silver metal particles, silver salt particles, and silver oxide particles.Furthermore, based on the total weight of the antiviral composition, the total content of silver metal particles, silver salt particles, and silver oxide particles is 0.01wt% or more.

[0030] In one embodiment, the metal-containing particles are selected from at least one of the group consisting of silver metal particles, silver salt particles, and silver oxide particles, and the metal in the metal-containing particles is selected from two or more of the group consisting of titanium, aluminum, nickel, cobalt, copper, zinc, iron, and manganese. In one embodiment, the corresponding ionic states of at least three of the three or more metal elements (i.e., silver and two or more others) may have different valences.

[0031] Inorganic metal-containing particles have lower resistance to chemicals compared to common organic (e.g., phenols) or non-metallic (e.g., nitroso- or peroxide-containing compounds) chemical antifungal, antibacterial, and antiviral agents. In addition, inorganic metal-containing particles have better slow-release properties, longer antifungal, antibacterial, and antiviral effects, and / or better durability. In addition, inorganic metal-containing particles are essentially non-volatile, making them safer and allowing them to be used on objects that come into contact with the human body.

[0032] In one embodiment, two or more different metal elements are selected in the metal-containing particles, so that due to the different redox potentials and / or different valences of different metal elements, the corresponding antifungal, antibacterial, antiviral effects may be correspondingly different.In this way, the antiviral composition can be widely used for antifungal, antibacterial, antiviral applications, and can have better / broader range of antifungal, antibacterial, antiviral effects.

[0033] In one embodiment, the resin material in the antiviral composition may include a photocurable resin. The photocurable resin may be cured by at least illumination. In one embodiment, the photocurable resin may be cured by exposure to ultraviolet light. In one embodiment, the photocurable resin may include poly(methyl methacrylate) (PMMA), fatty polyurethane, or copolymers thereof (e.g., polyurethane prepolymer fatty polyurethane acrylate).

[0034] In one embodiment, the content of poly(methyl methacrylate), aliphatic polyurethane or copolymer thereof may be in the range of 20 wt% to 60 wt% based on the total weight of the antiviral composition.

[0035] In one embodiment, the resin material in the antiviral composition can further include epoxy resin, epoxy acrylate, polyurethane acrylate, polyester acrylate, polyether acrylate, pure acrylic resin, silicone oligomer, or combination thereof, but the present invention is not limited thereto. Based on the total weight of the antiviral composition, the content of epoxy resin, epoxy acrylate, polyurethane acrylate, polyester acrylate, polyether acrylate, pure acrylic resin, silicone oligomer, or combination thereof can be between 32wt% and 79.9wt%.

[0036] In one embodiment, the method for producing the antiviral protective film may include the following steps: the antiviral composition is coated on the surface of the base layer by coating. The antiviral composition coating the base layer is then cured by a suitable curing method (e.g., photocuring) to form an antiviral layer. On the other side of the base layer, a corresponding adhesive layer and / or release layer may be formed at a suitable time (e.g., after forming the antiviral layer or before coating the antiviral composition).

[0037] In one embodiment, the thickness of the antiviral layer can be between 0.02mm and 0.5mm. If the thickness of the antiviral layer is too thick (e.g., more than 0.5mm), the cost may increase and / or the overall light transmittance or appearance of the antiviral protective film may be affected. If the thickness of the antiviral layer is too thin (e.g., less than 0.02mm), the antiviral layer is more likely to be damaged (although this is not necessarily the case).

[0038] In one embodiment, the antiviral layer can be a stack of multiple film layers, further comprising at least one layer formed from the antiviral composition. EXAMPLES

[0039] [Examples and Comparative Examples] The present invention will be described in detail below with reference to examples and comparative examples, but the present invention is not limited to the following examples in any way.

[0040] According to each of the examples and comparative examples, the corresponding antiviral protective film can be formed according to the above-mentioned method. In each of the examples and comparative examples, the material and / or structure (such as thickness or relative position) of each layer is basically the same, and the difference between them is the type or corresponding loading amount of metal-containing particles in the composition forming the antiviral layer (or a similar film layer with the same structure but different materials).

[0041] The compositions and corresponding evaluation items of [Examples 1] to [Examples 3] and [Comparative Example] are shown in [Table 1].

[0042] In the following examples and comparative examples, antifungal evaluation can be performed according to the ASTM G21 standard practice for determining the resistance of synthetic polymeric materials to fungi established by the American Society for Testing and Materials (ASTM). If an evaluation target (such as the embodiment or comparative example described below) has an antifungal effect of grade 0 (i.e., no fungal growth) against the test fungus, it means that the evaluation target has an antifungal effect against the test fungus.

[0043] In the following Examples and Comparative Examples, antibacterial evaluation was performed in accordance with the antibacterial test standard (antibacterial processed products - antibacterial test method, antibacterial effect) of JIS (Japanese Industrial Standards) Z2801. If the antibacterial activity value of the evaluation target (such as the Examples or Comparative Examples described below) against the test culture is 2.0 or more, it means that the evaluation target has an antibacterial effect against the test culture.

[0044] In the following examples and comparative examples, the antiviral evaluation was performed according to the ISO 21702:2019 antiviral detection standard (measurement of antiviral activity against plastics and other non-porous surfaces) established by the ISO (International Organization for Standardization). If the antiviral activity value of the evaluation target (such as the examples or comparative examples described below) against the test virus is 2.0 or more, it means that it has an antiviral effect against the test virus.

[0045] The antifungal, antibacterial, and / or antiviral testing, evaluation, or identification may be performed by a third party impartial unit such as, for example, but not limited to, the Societe Generale de Surveillance (SGS) or a testing unit certified by SGS, or a testing unit certified by Nippon BOKEN (General Financial Institutions Foundation BOKEN Quality Evaluation Agency) or a testing unit certified by Nippon BOKEN.

[0046] In the following examples and comparative examples, the visible light transmittance (VLT) and / or haze in the visible light wavelength range can be measured by a Hunterlab®-UltraScan PRO spectrophotometer. In addition, the values ​​shown in the examples and comparative examples can be relative values ​​(e.g., equivalent to the same specification product).

[0047] [Table 1]

[0048] In addition, for [Example 1] and [Example 2], the antifungal effect was evaluated using one of Aspergillus niger, Penicillium tetrapine, Chaetomium globosum, Gliocladium virens, and Aureobasidium pullulans, and the antifungal effect of both [Example 1] and [Example 2] was Grade 0.

[0049] Furthermore, for [Example 1] and [Example 2], further evaluation of the antifungal effect was performed using one of Aspergillus niger, Penicillium tetrapinus, Chaetomium globosum, Gliocladium virens, and Aureobasidium pullulans in the test, and the antifungal effect of both [Example 1] and [Example 2] was Grade 0.

[0050] In addition, further evaluation of the antifungal effect of [Example 3] was performed using one of Aspergillus niger, Penicillium tetrapinus, Chaetomium globosum, Gliocladium virens, and Aureobasidium pullulans in the test, and it appears that the antifungal effect of [Example 3] is probably Grade 1 (the fungus grows, but the area of ​​fungal growth is less than 10%).

[0051] Furthermore, for [Example 1] and [Example 2], further antibacterial effect evaluation was performed using one of the following bacteria: Streptococcus pneumoniae, Escherichia coli, Staphylococcus aureus, drug-resistant Staphylococcus aureus, Salmonella, and Pseudomonas aeruginosa. The antibacterial activity values ​​of [Example 1] and [Example 2] were both 2.0 or higher.

[0052] Taking [Example 2] as an example, the antibacterial activity values ​​of each test culture were as follows: Pneumococcus was greater than 5.76, Escherichia coli was about 4.16, Staphylococcus aureus was about 2.90, drug-resistant Staphylococcus aureus was about 3.60, Salmonella was about 2.59, and Pseudomonas aeruginosa was greater than 5.10.

[0053] When compared with the same specific test culture, the antibacterial effect of [Example 1] is superior to that of [Example 2].

[0054] Further, when the antiviral effect of [Example 1] was further evaluated and the H1N1 influenza virus was used in the test, the antiviral activity value of [Example 1] was about 3.9.

[0055] Furthermore, when comparing [Example 1] to [Example 3] with [Comparative Example], the appearance (e.g., visible light transmittance and / or haze) and / or practicality (e.g., scratch resistance) of the antiviral protective film within the corresponding range of metal-containing particle addition may all be within the acceptable range for general industrial use.

[0056] In summary, the antiviral composition of the present invention and / or the antiviral protective film formed by the antiviral composition may have better antifungal, antibacterial and / or antiviral effects. [Industrial Applicability]

[0057] The antiviral composition of the present invention can form a corresponding antiviral protective film.The antiviral protective film of the present invention can be coated (e.g., by adhesion) on the surface of electronic products that are suitable for contact (e.g., mobile phones or touch screens, but the present invention is not limited thereto), or on the surface of objects that can contact public environments (e.g., desktops, chair surfaces, countertops, medical equipment, etc., but the present invention is not limited thereto).In this way, the antiviral layer facing outward can reduce the attachment and / or proliferation of pathogens on the layer. [Explanation of symbols]

[0058] 100 Antiviral Protective Film 110 Antiviral Layer 120 Base Layer 130 Adhesive layer 140 Peeling layer 240 Objects

Claims

1. 1. An antiviral composition comprising: A resin material; The antiviral composition contains 0.016% by weight of silver phosphate, 0.240% by weight of zinc oxide, and 0.008% by weight of titanium dioxide as metal-containing particles having a particle diameter in the range of 2 nm to 200 nm, based on the total weight of the antiviral composition; The antiviral composition has an antiviral activity value of 2.0 or more according to the ISO 21702:2019 antiviral test standard.

2. 2. The antiviral composition of claim 1, wherein the resin material comprises poly(methyl methacrylate), aliphatic polyurethane, or copolymers thereof.

3. 3. The antiviral composition according to claim 2, wherein the content of poly(methyl methacrylate), the content of aliphatic polyurethane, or the content of a copolymer thereof is in the range of 20 wt % to 60 wt % based on the total weight of the antiviral composition.

4. 3. The antiviral composition of claim 2, wherein the resin material further comprises an epoxy resin, an epoxy acrylate, a polyurethane acrylate, a polyester acrylate, a polyether acrylate, a pure acrylic resin, a silicone oligomer, or a combination thereof.

5. An antiviral protective film, A base layer; an antiviral layer disposed on the surface of the base layer and formed by the antiviral composition of claim 1; and an adhesive layer disposed on the other surface of the base layer, the base layer being disposed between the antiviral layer and the adhesive layer; An anti-viral protective film.

6. The antiviral protective film of claim 5 , further comprising a release layer disposed on the adhesive layer.

7. A method for producing an antiviral protective film, comprising: disposing a base layer; Coating the base layer with the antiviral composition of claim 1 to form an antiviral layer; A manufacturing method comprising:

Citation Information

Patent Citations

  • virucidal material

    JP2009526828A

  • Environmental substance-treating agent

    JP2010270079A

  • Antimicrobial coating material, method for producing antimicrobial coating material, antimicrobial coating, and antivirus tape

    JP2021178954A

  • JPP6911993B

  • Antiviral transfer sheet and method for producing same, and antiviral shrink film and method for producing same

    WO2016084774A1